See ratings and reviews when you sign up for an account.

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

This study is currently Recruiting

February 2011 By University of Maryland

First Recieved on October 24, 2008

Last Updated on February 7, 2011

Sponsor: University of Maryland
Information provided by: University of Maryland
Identifier: NCT00780650


This study is aimed at determining if the drug Atomoxetine (Strattera-used to treat Attention Deficit Hyperactivity Disorder(ADHD) has effects on the body's ability to defend itself against low blood sugar.

Study Type: Interventional
Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers

Inclusion Criteria: - Healthy individuals aged 18-50 years - Type 1 Diabetes individuals aged 18-50 years - BMI <40 kg/m2 - Females of childbearing potential with negative urine pregnancy test - Volunteers over 40 years of age, a cardiac stress test with no clinically significant conduction or ischemic changes Exclusion Criteria: The following groups of subjects will be excluded from the study: - Pregnant women - Subjects unable to give voluntary informed consent - Subjects on anticoagulant drugs or with known bleeding diatheses - Subjects with uncontrolled hypertension, heart disease, cerebrovascular incidents - Subjects taking MAOIs - Subjects with narrow angle glaucoma - Subjects with diagnosed psychiatric disorders - Subjects with allergy to atomoxetine, heparin, or lidocaine Physical Exam Exclusion Criteria: - Uncontrolled severe hypertension (i.e., blood pressure greater than 150/95) - Clinically significant Cardiac Abnormalities (e.g. Heart Failure, Arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects > 40 years old. - Pneumonia - Hepatic Failure/Jaundice - Renal Failure - Acute Cerebrovascular/ Neurological deficit - Fever greater than 38.0 C Screening Laboratory Tests Exclusion Criteria Blood values as defined in protocol


  • Investigator: Stephen N. Davis, MD - Principal Investigator - University of Maryland


  • Univerisity of Maryland, Baltimore

    Baltimore, Maryland 21201 United States

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.